This Article Full Text Full Text (PDF) Related Article Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hsing, A. W. Articles by Stanczyk, F. Z. Search for Related Content PubMed PubMed Citation Articles by Hsing, A. W. Articles by Stanczyk, F. Z. Related Collections Commentary Key Article

Androgen and Prostate Cancer: Is the Hypothesis Dead?

¹ Division of Cancer Epidemiology and Genetics, and ² Office of Preventive Oncology, National Cancer Institute, NIH, Bethesda, Maryland; and ³ Departments of Obstetrics and Gynecology, and ⁴ Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California

Requests for reprints: Ann W. Hsing, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Plaza South 5024, MSC 7234, 6120 Executive Boulevard, Bethesda, Maryland 20892. Phone: 301-496-1691; Fax: 301-402-0916. E-mail: hsinga{at}mail.nih.gov

Data from animal, clinical, and prevention studies support the role of androgen in prostate cancer growth, proliferation, and progression. However, results serum-based epidemiologic studies in humans have been inconclusive. Part of the inconsistency in these findings stems from differences in study population, assay accuracy, intraperson variation, and limited sample size. Recently, data from a large pooled analysis of 18 prospective studies (3,886 cases and 6,438 healthy controls) showed no association between serum androgen and prostate cancer risk. It is not surprising that the pooled analysis did not find a positive link between circulating levels of total testosterone and prostate cancer risk because, individually, few of the 18 studies included in the pooled analysis reported a substantial positive association. The null result, however, does not pronounce a death sentence for the androgen hypothesis; rather, it underscores the importance of a better understanding of androgen action within the prostate, including the relationship between tissue and serum levels of androgen. In this commentary, we explain why circulating levels of testosterone may not reflect androgen action in the prostate and why tissue levels of androgen, in particular dihydrotestosterone, and the androgen receptor and its coregulators are critical to androgen action in the prostate and should be incorporated in future studies. It is timely to integrate system thinking into our research and use an interdisciplinary approach that involves different disciplines, including epidemiology, endocrinology, pathology, and molecular biology, to help dissect the complex interplay between sex steroids and genetic and lifestyle factors in prostate cancer etiology. (Cancer Epidemiol Biomarkers Prev 2008;17(10):2525–30)

Key Article

Colorectal Cancer Is an Ambulatory Care Sensitive Condition

Mona Sarfaty and Elaine Yuen
Cancer Epidemiol. Biomarkers Prev. 2008 17: 2531-2535. [Abstract] [Full Text] [PDF]